Lack of prognostic relevance of Her-2/neu, topoisomerase IIα and EGFR in advanced ovarian carcinoma

Engelstaedter,Verena; Boda,Judith; Völklein,Christine; Engel,Jutta; Jeschke,Udo; Kirchner,Thomas; Mayr,Doris

doi:10.3892/etm.2012.481

Lack of prognostic relevance of Her-2/neu, topoisomerase IIα and EGFR in advanced ovarian carcinoma

Authors:
- Verena Engelstaedter
- Judith Boda
- Christine Völklein
- Jutta Engel
- Udo Jeschke
- Thomas Kirchner
- Doris Mayr
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Ludwig-Maximilians University, D-80337 Munich, Germany, Institute of Pathology, Ludwig-Maximilians University, D-80337 Munich, Germany, Munich Cancer Registry, Ludwig-Maximilians University, D-81377 Munich, Germany
Published online on: February 13, 2012 https://doi.org/10.3892/etm.2012.481
Pages: 828-834

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Patients with advanced ovarian cancer (FIGO stage III) have a poor clinical prognosis. However, these patients show distinct differences in their survival time, possibly due to differing responses to chemotherapy and differing tumor biology. In contrast to histological subtype, grading and staging, which are known to affect a patient's prognosis, the impact of the human epidermal growth factor receptor 2 (Her-2/neu), topoisomerase IIα and epidermal growth factor receptor (EGFR) on survival remain inconclusive. Therefore, the aim of this study was to assess their impact on survival in a group of advanced ovarian cancer patients. Tissue microarrays were constructed from specimens of 243 patients. Gene copy and chromosome numbers were evaluated by fluorescence in situ hybridization (FISH) and protein expression by immunohistochemistry (IHC). Scoring for the latter was calculated by considering the percentage of positive tumor cells and the relative staining intensity. FISH results were evaluated by previously published recommendations and correlated with overall survival. Using IHC, 1.6% of the cases that were tested for Her-2/neu and topoisomerase IIα were strongly positive, and 12.3% were positive for EGFR. Using FISH, 4.4% amplifications and 2.1% polysomies for Her-2/neu were identified; topoisomerase IIα showed 2.2% amplifications, 0.4% deletions and 3.5% polysomies. We observed 10.8% high polysomies, but no amplification for EGFR. None of the results obtained by IHC or FISH correlated with overall survival. In general, Her-2/neu, topoisomerase IIα and EGFR may be prognostic factors in ovarian carcinomas. However, within this group of FIGO stage III patients, differences in gene aberration or protein expression were not able to predict differences in survival.

View Figures

View References

1.	Robert Koch-Institut und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. Berlin. Krebs in Deutschland 2003–2004 Häufigkeit und Trends. 6th edition. 2008
2.	Statistisches Bundesamt: Todesursachenstatistik in Deutschland. Fachserie 12, Reihe 4,. pp. 1–114. 2008
3.	Deutsche Krebsgesellschaft e. V. Krebshäufigkeit - die aktuellen Zahlen,. 2007
4.	Dietel M: Ovar: tumoren. Pathologie. Remmele W: 4. 2nd edition. Springer-Verlag; Berlin Heidelberg: pp. 92–123. 1992
5.	Olsen CM, Cnossen J, Green AC, et al: Comparison of symptoms and presentation of women with benign, low malignant potential and invasive ovarian tumors. Eur J Gynaecol Oncol. 28:376–380. 2007.PubMed/NCBI
6.	Cannistra SA: Cancer of the ovary. N Engl J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
7.	Goff BA, Muntz HG, Greer BE, et al: Oncogene expression: long-term compared with short-term survival in patients with advanced epithelial ovarian cancer. Obstet Gynecol. 92:88–93. 1998. View Article : Google Scholar : PubMed/NCBI
8.	Kaern J, Aghmesheh M, Nesland JM, et al: Prognostic factors in ovarian carcinomas stage III patients. Can biomarkers improve the prediction of short- and long-term survivors? Int J Gynecol Cancer. 15:1014–1022. 2005. View Article : Google Scholar : PubMed/NCBI
9.	Schindlbeck C, Hantschmann P, Zerzer M, et al: Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIalpha, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow. Int J Gynecol Cancer. 17:1047–1055. 2007. View Article : Google Scholar
10.	Faggad A, Darb-Esfahani S, Wirtz R, et al: Topoisomerase IIalpha mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis. Mod Pathol. 22:579–588. 2009. View Article : Google Scholar : PubMed/NCBI
11.	De Graeff P, Crijns AP, de Jong S, et al: Modest effect of p53, EGFR and Her-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J cancer. 101:149–159. 2009.PubMed/NCBI
12.	Wang JC: Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol. 3:430–440. 2002. View Article : Google Scholar : PubMed/NCBI
13.	World Health Organization: Pathology & Genetics. Tumours of the Breast and Female Genital Organs. IARC Press; Lyon: 119. 2003
14.	Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 131:18–43. 2007.
15.	Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohisto-chemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 8:138–140. 1987.(In German).
16.	Chekerov R, Klaman I, Zafrakas M, et al: Altered expression pattern of topoisomerase IIα in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy. Neoplasia. 8:38–45. 2006.
17.	Pauletti G, Godolphin W, Press MF, et al: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 13:63–72. 1996.PubMed/NCBI
18.	Cappuzzo F, Hirsch FR, Rossi E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 97:643–655. 2005. View Article : Google Scholar : PubMed/NCBI
19.	Serrano-Olvera A, Duenas-Gonzalez A, Gallardo-Rincón D, et al: Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev. 32:180–190. 2006. View Article : Google Scholar : PubMed/NCBI
20.	Lee ES, Lee Y, Suh D, et al: Detection of HER-2 and EGFR gene amplification using chromogenic in-situ hybridization technique in ovarian tumors. Appl Immunohistochem Mol Morphol. 18:69–74. 2010. View Article : Google Scholar : PubMed/NCBI
21.	Vermeij J, Teugels E, Bourgain C, et al: Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. BMC cancer. 8:32008. View Article : Google Scholar : PubMed/NCBI
22.	Dimova I, Raicheva S, Dimitrov R, et al: Coexistence of copy number increases of c-Myc, ZNF217, CCND1, ErbB1 and ErbB2 in ovarian cancers. Onkologie. 32:405–410. 2009. View Article : Google Scholar : PubMed/NCBI
23.	De Graeff P, Crijns AP, Ten Hoor HK, et al: The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer. 99:341–349. 2008.PubMed/NCBI
24.	Farley J, Fuchiuji S, Darcy KM, et al: Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study. Gynecol Oncol. 113:341–347. 2009. View Article : Google Scholar
25.	Durbecq V, Paesmans M, Cardoso F, et al: Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther. 3:1207–1214. 2004.
26.	Schindlbeck C, Mayr D, Olivier C, et al: Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer. J Cancer Res Clin Oncol. 136:1029–1037. 2010. View Article : Google Scholar
27.	Lassus H, Sihto H, Leminen A, et al: Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med. 84:671–681. 2006. View Article : Google Scholar : PubMed/NCBI
28.	Tanaka Y, Terai Y, Tanabe A, et al: Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer. Cancer Biol Ther. 11:50–57. 2011. View Article : Google Scholar : PubMed/NCBI
29.	Stadlmann S, Gueth U, Reiser U, et al: Epithelial growth factor receptor status in primary and recurrent ovarian cancer. Mod Pathol. 19:607–610. 2006. View Article : Google Scholar : PubMed/NCBI
30.	Tanner B, Hasenclever D, Stern K, et al: ErbB-3 predicts survival in ovarian cancer. J Clin Oncol. 24:4317–4323. 2006. View Article : Google Scholar : PubMed/NCBI
31.	Garcia-Velasco A, Mendiola C, Sanchez-Munoz A, et al: Prognostic value of hormonal receptors, p53, ki67 and Her2/neu expression in epithelial ovarian carcinoma. Clin Transl Oncol. 10:367–371. 2008. View Article : Google Scholar : PubMed/NCBI